[Therapeutic activity of Oriprim in bronchopulmonary diseases].
A new chemotherapeutic drug oriprim was used for therapy of 36 patients with bronchopulmonary pathology. Its therapeutic efficacy was noted in 83.3% of the cases. In 6 patients oriprim therapy turned out to be ineffective as a result of early side-effects. The drug was effective in pneumococcal infection. In suspicion of anaerobic infection (B. fragilis, etc) oriprim was given in combination with metronidazole.
D000284:Administration, Oral; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000008:administration & dosage; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae; D006801:Humans; D007273:Injections, Intramuscular; D011014:Pneumonia / Q000188:drug therapy*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy; D013212:Staphylococcus epidermidis; D013420:Sulfamethoxazole / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Izuchenie terapevticheskoĭ aktivnosti Oriprima pri bronkholegochnykh zabolevaniiakh.